StockNow
CalendarLog in
U.S. Markets

Biogen (BIIB) notes Phase 3 Pediatric EMPAVELI data show reduction in proteinuria and stabilized kidney function in adolescents with C3G

StockNow breaking-news AI analysis

Biogen announced CJASN publication of Phase 3 VALIANT data showing EMPAVELI achieved a 75% proteinuria reduction and stabilized kidney function in adolescents with C3G and primary IC-MPGN.

1 stocks
BIIBBiogen Inc. Common Stock$219.04Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

US President Trump told Axios he is at a "critical juncture" regarding the war in Iran, weighing whether to launch massive new attacks or pursue a different path to end the conflict

Geopolitics

US approves visas for top Iranian leaders to attend UN high-level meeting even with sides at war, reports AP

Geopolitics

UK MTO says it received a report of a security incident in Strait of Hormuz 16 NM Northeast of Khasab, Oman